Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Baxter
Moodys
AstraZeneca
Mallinckrodt

Last Updated: August 11, 2022

Investigational Drug Information for TRC105


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug TRC105?

TRC105 is an investigational drug.

There have been 21 clinical trials for TRC105. The most recent clinical trial was a Phase 3 trial, which was initiated on February 13th 2017.

The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are Tracon Pharmaceuticals Inc., National Cancer Institute (NCI), and University of Alabama at Birmingham.

There are two US patents protecting this investigational drug and sixty-six international patents.

Recent Clinical Trials for TRC105
TitleSponsorPhase
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerEnviro Therapeutics, Inc.Phase 1
Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung CancerKaren Reckamp, MD, MSPhase 1
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on TherapyCedars-Sinai Medical CenterPhase 2

See all TRC105 clinical trials

Clinical Trial Summary for TRC105

Top disease conditions for TRC105
Top clinical trial sponsors for TRC105

See all TRC105 clinical trials

US Patents for TRC105

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TRC105 See Plans and Pricing Methods of administering IgG1 antibodies and methods of suppressing angiogenesis University of Kentucky Research Foundation (Lexington, KY) See Plans and Pricing
TRC105 See Plans and Pricing Posterior segment drug delivery ForSight Vision4, Inc. (Menlo Park, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TRC105

Drugname Country Document Number Estimated Expiration Related US Patent
TRC105 Canada CA2907548 2033-03-13 See Plans and Pricing
TRC105 European Patent Office EP2968556 2033-03-13 See Plans and Pricing
TRC105 World Intellectual Property Organization (WIPO) WO2014160336 2033-03-13 See Plans and Pricing
TRC105 Australia AU2010208046 2029-01-29 See Plans and Pricing
TRC105 Australia AU2011285501 2029-01-29 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Baxter
Moodys
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.